Patents by Inventor Timothy D. Bartley
Timothy D. Bartley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6479250Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: July 7, 2000Date of Patent: November 12, 2002Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
-
Patent number: 6169167Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.Type: GrantFiled: March 25, 1998Date of Patent: January 2, 2001Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Gary M. Fox
-
Patent number: 6087167Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: October 28, 1997Date of Patent: July 11, 2000Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
-
Patent number: 6063903Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.Type: GrantFiled: March 25, 1998Date of Patent: May 16, 2000Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Gary M. Fox
-
Patent number: 6057124Abstract: Polypeptides which bind to one or more EPH-like receptors, particularly the HEK4 receptor, are described. The polypeptides are designated HEK4 binding proteins. Nucleic acids encoding HEK4 binding proteins, and expression vectors, host cells and processes for the production of the polypeptides are also described. The polypeptides are useful for modulating the growth and/or differentiation of a variety of tissues, including those from liver, kidney, lung, skin, digestive tract and nervous system and may be used to regenerate damaged or depleted tissue and to treat cancer or nervous system disorders.Type: GrantFiled: January 27, 1995Date of Patent: May 2, 2000Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Gary M. Fox
-
Patent number: 5824303Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: May 19, 1995Date of Patent: October 20, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
-
Patent number: 5795569Abstract: Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands or thrombopoietin, that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.Type: GrantFiled: October 12, 1994Date of Patent: August 18, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Jakob M. Bogenberger, Robert A. Bosselman, Pamela Hunt, Olaf B. Kinstler, Babru B. Samal
-
Patent number: 5766581Abstract: Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands), that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. The MGDF proteins and derivatives are useful in methods for treating mammals to increase platelets and/or megakaryocytes. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.Type: GrantFiled: March 30, 1995Date of Patent: June 16, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, Jakob M. Bogenberger, Robert A. Bosselman, Pamela Hunt, Olaf B. Kinstler, Babru B. Samal
-
Patent number: 5716934Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: May 30, 1995Date of Patent: February 10, 1998Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Vann P. Parker, Gary M. Fox, Andrew A. Welcher
-
Patent number: 5650504Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.Type: GrantFiled: May 24, 1995Date of Patent: July 22, 1997Assignee: Amgen Inc.Inventors: Timothy D. Bartley, William J. Boyle, Vann P. Parker, Gary M. Fox, Andrew A. Welcher